PerkinElmer, Inc.

719 articles with PerkinElmer, Inc.

• PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2019

  1/27/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended December 29, 2019.

• PerkinElmer Board Declares Quarterly Dividend payable on May 8, 2020

  1/23/2020

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on January 23, 2020.

• PerkinElmer Provides Newborn Screening Solution for Duchenne Muscular Dystrophy as part of PPMD’s New York State Pilot Program

  1/13/2020

  First Infant Recently Screened for Most Prevalent Type of Muscular Dystrophies

• PerkinElmer to Hold Earnings Call on Monday, January 27, 2020

  1/7/2020

  PerkinElmer, Inc. announced that on Monday, January 27, 2020, after market close, the Company will release fourth quarter 2019 results. The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results.

• PerkinElmer to Present at J.P. Morgan Healthcare Conference

  12/19/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 3:30 p.m.

• PerkinElmer Launches First FDA-Approved Assay Kit to Screen for Duchenne Muscular Dystrophy in Newborns

  12/13/2019

  PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that its GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has received U.S. Food & Drug Administration (FDA) approval.

• PerkinElmer Solution to Analyze Microplastics During Two Year, All-Women Research Voyage of World’s Oceans

  11/14/2019

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced its Spectrum Two™ FT-IR spectrometer solution is onboard a research trip led by eXXpedition, a not-for-profit organization running all-women sailing voyages investigating ocean plastic pollution causes and solutions.

• PerkinElmer Announces Financial Results for the Third Quarter of 2019

  10/30/2019

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, reported financial results for the third quarter ended September 29, 2019.

• PerkinElmer Genomics’ Clinical Labs in U.S. and Malaysia to Process Samples with Vanadis Fully Automated NIPT Platform

  10/29/2019

  Technology Provides Pregnant Women Widespread NIPT Access

• PerkinElmer to Present at Wolfe Research Healthcare Conference

  10/25/2019

  PerkinElmer, Inc announced that the Company will present at the Wolfe Research Healthcare Conference on Wednesday, November 6, 2019, at 8:00 a.m. ET at the Marriott East Side Hotel in New York.

• PerkinElmer Board Declares Quarterly Dividend payable on February 7, 2020

  10/24/2019

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on October 24, 2019.

• PerkinElmer Launches PG-Seq™ Rapid Non-Invasive Preimplantation Genetic Testing Kit as Alternative to IVF Embryo Biopsies

  10/14/2019

  New kit shown to achieve over 90% correlation rate between biopsied embryos and testing spent culture media

• PerkinElmer to Hold Earnings Call on Wednesday, October 30, 2019

  10/7/2019

  The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results.

• PerkinElmer Announces Redemption of 5% Senior Unsecured Notes Due in 2021

  9/13/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it is giving notice of the redemption of all of its outstanding 5% Senior Unsecured Notes due in 2021 (the “2021 Notes”).

• PerkinElmer Prices Offering of Senior Notes

  9/10/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of $850 million aggregate principal amount of 3.300% Senior Notes due 2029 at an issue price of 99.670% of the principal amount.

• Clinical Study Published in Prenatal Diagnosis Further Validates PerkinElmer’s Vanadis Fully Automated NIPT Platform

  8/21/2019

  CE-Marked Solution Gives Pregnant Women Widespread Access to Non-Invasive Prenatal Testing

• PerkinElmer Announces Leadership Succession Plan

  8/21/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that after a career of more than 20 years at the Company, including the last 12 years as chief executive officer, Robert F. Friel, has decided to retire as chairman and CEO and member of the board of directors as of the end of the Company’s fiscal year on December 29, 2019.

• PerkinElmer Launches EUROIMMUN ELISA for Detection of Aspergillus Infections

  8/5/2019

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of the new EUROIMMUN Aspergillus Antigen ELISA.

• PerkinElmer Announces Financial Results for the Second Quarter of 2019

  7/29/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended June 30, 2019.

• PerkinElmer Board Declares Quarterly Dividend payable on November 8, 2019

  7/25/2019

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on July 25, 2019.